LXRX Healthcare

Lexicon Pharmaceuticals, Inc.

$1.46+1.39%

Price as of close on Nov 3, 2026 · Financials updated Oct 9, 2026

Basics

Sector: Healthcare
Industry: Biotechnology
Country: United States
Market cap: 649.6M USD
Enterprise value: 537.2M USD
Full-time employees: 81

Overall health

Strength: growing faster than most peersgrowing faster than peers
Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity
Drawback: less profitable than most peersless profitable than peers
Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings
Drawback: its share price swings more than most peers’ (beta 1.08 vs a peer median of 0.63)bigger price swings (beta 1.08 vs peers 0.63)

Ranks #671 of 1,157 healthcare companies (bottom 43%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 25% of revenue in 2025.
Lexicon Pharmaceuticals paid employees $13M in stock in 2025, 25% of its $50M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.
Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.
Relative to its free cash flow, Lexicon Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.
Not profitable yet. Reported a loss in the 12 months to June 2026.
Lexicon Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.
Revenue is falling. Revenue fell 29% in the 12 months to June 2026 vs the 12 months before.
Lexicon Pharmaceuticals's revenue fell 29% in the 12 months to June 2026 vs the 12 months before.

StockQuotient Score

48/ 100

Oct 5 48 → Nov 4 48

Valuation

Is the price right?

8/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major changeValuation also moves with the share price every day.

Why

Weaker than most peers on:

▼ Earnings yield
▼ EBITDA yield

Compare with peers

Behind the score

Sector-normalized EBITDA, earnings, and free cash flow yields.

Earnings yield-9.4%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price30% base weight · Z-score -1.00Sector median: 0.0148 · MAD: 0.0148

EBITDA yield-10.6%

SEC filings · 12 months to Jun 2026Negative (a loss or cash outflow), so it counts as zero whatever the share price50% base weight · Z-score -1.00Sector median: 0.0401 · MAD: 0.0401

Free cash flow yield-10.0%

SEC filings · 12 months to Jun 2026 · operating cash flow − capital spendingNegative (a loss or cash outflow), so it counts as zero whatever the share price20% base weight · Z-score 0.00Sector median: 0.0000 · MAD: 0.0000

Other data (not scored)

Book yield26.9%

SEC filings · latest balance sheetReported valueInformational · 0% composite weightSector median: 0.3716 · MAD: 0.2313

Growth

Is it growing?

81/100

Strong

3/3 inputs reported · High confidence

Since last quarter: ▼ Weaker

12-month revenue fell 40.5%

Why

Stronger than most peers on:

▲ 3-yr revenue

Compare with peers

Behind the score

Revenue and earnings-per-share growth over one year, and revenue growth over three years.

Earnings per share growthUnavailable

Still loss-making, but the loss per share narrowed33% base weight · Z-score 0.29Sector median: 0.0976 · MAD: 0.2991

3-year revenue growth367.1%

SEC filings · 3 years to Jun 2026Outlier capped at sector 5th/95th percentile33% base weight · Z-score 8.59Sector median: 0.0584 · MAD: 0.0840

Revenue growth-29.0%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -3.60Sector median: 0.0609 · MAD: 0.0974

Profitability

Does it earn well?

16/100

Weak

3/3 inputs reported · High confidence

Since last quarter: No major change

Why

Weaker than most peers on:

▼ Operating margin
▼ ROA
▼ ROIC

Compare with peers

Behind the score

Return on invested capital, operating margin, and return on assets.

Operating margin-131.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -11.38Sector median: 0.0706 · MAD: 0.1217

Return on assets-24.4%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -4.86Sector median: 0.0166 · MAD: 0.0537

Return on invested capital-23.3%

SEC filings · 12 months to Jun 2026Reported value33% base weight · Z-score -2.79Sector median: 0.0471 · MAD: 0.1004

Other data (not scored)

Gross margin99.1%

SEC filings · 12 months to Jun 2026Outlier capped at sector 5th/95th percentileInformational · 0% composite weightSector median: 0.4697 · MAD: 0.2310

Return on equity-35.0%

SEC filings · 12 months to Jun 2026Reported valueInformational · 0% composite weightSector median: 0.0330 · MAD: 0.1225

Risk

Debt, liquidity, price swings

Lower

Lower relative risk

3/3 inputs reported · High confidence

Since last quarter: No major change

Why it changed since the Oct 27, 2026 close: Safety percentile 89 → 88

Peer companies moved-1

Each step re-scores the company against its peers as they were on Oct 28, 2026; the parts add up to the change. Price effects on EBITDA yield are approximate.

Why

Stronger than most peers on:

▲ Current ratio

Compare with peers

Behind the score

Relative to sector peers: 0 = lower relative risk · 1 = moderate · 2 = higher. Based on leverage, beta and liquidity.

Beta1.08

Yahoo Finance · 5-year monthly beta vs the marketReported value33% base weight · Z-score -1.34Sector median: 0.6250 · MAD: 0.3380

Current ratio13.37×

SEC filings · latest balance sheetReported value33% base weight · Z-score 7.78Sector median: 2.5860 · MAD: 1.3850

Debt / equity0.29×

SEC filings · latest balance sheetReported value33% base weight · Z-score -0.36Sector median: 0.2215 · MAD: 0.2039

Valuation, growth and profitability scores: higher is better. Risk: 0 is lower, 2 is higher. Risk is a relative proxy, not a bankruptcy probability. Scores depend on available sector peers.

Questions investors ask about Lexicon Pharmaceuticals

Is Lexicon Pharmaceuticals getting weaker?: Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 40.5%. Its overall score is unchanged at 48/100 since Oct 28, 2026.
How is Lexicon Pharmaceuticals valued vs its peers?: Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.4% vs peers 1.5% (weaker than 100% of peers).
Is Lexicon Pharmaceuticals growing?: Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers. 3-year revenue growth 367.1% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 367.1% vs peers 5.8% (stronger than 95% of peers). Revenue growth -29.0% vs a peer median of 6.1% (weaker than 93% of peers).Revenue growth -29.0% vs peers 6.1% (weaker than 93% of peers).
How profitable is Lexicon Pharmaceuticals?: Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Operating margin -131.4% vs a peer median of 7.1% (weaker than 88% of peers).Operating margin -131.4% vs peers 7.1% (weaker than 88% of peers).
How risky is Lexicon Pharmaceuticals?: Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 13.37× vs a peer median of 2.59× (stronger than 91% of peers).Current ratio 13.37× vs peers 2.59× (stronger than 91% of peers). Beta 1.08 vs a peer median of 0.63 (weaker than 75% of peers).Beta 1.08 vs peers 0.63 (weaker than 75% of peers). A relative measure, not a bankruptcy probability.

Latest filing: what changed

Quarter ended Jun 30, 2026 · filed Aug 6, 2026 · compared with the quarter ended Mar 31, 2026

Got weaker

12-month revenue fell 40.5%

Worth watching: Lexicon Pharmaceuticals is in the bottom fifth of its sector on profitability. From 2021 to 2025, 63% of companies in that position posted a loss over the following year, against 4% for the top fifth.

	Previous quarter	Latest quarter	Change
Revenue (12 months)	69.6M USD	41.5M USD	−40.5%
Net income (12 months)	−26.1M USD	−61.1M USD	+134.3%
Operating margin	-34.8%	-131.4%	−96.6 pts
Debt	49.7M USD	51.4M USD	+3.5%
Cash	38.1M USD	40.9M USD	+7.4%
Shares outstanding	444.2M	445.0M	+0.2%

From the company’s own SEC filings, as filed. Twelve-month figures roll forward one quarter at a time.

Industry valuation context

Industry: Biotechnology · 132 companies

Valuations in Biotechnology are within their usual range since 2016.

48% of months since 2016 were valued lower than now.
22% of companies are in the most expensive fifth of their own price-to-sales history.
Median price-to-sales is +530% vs the whole market, against a usual +637%.

2016Shaded: most expensive fifth of its range2026

Earnings-based measures are left out for now because many companies in Biotechnology are losing money.

Financials

Fiscal years from SEC annual filings · change vs the prior year

Key ratios	FY 2021	FY 2022	FY 2023	FY 2024	FY 2025	Change
Gross margin	100.0%	100.0%	92.9%	98.0%	99.4%	▲ 1.4 pts
Operating margin	-29224.8%	-72489.2%	-14265.0%	-634.2%	-98.2%	▲ 536 pts
Net margin	-29449.0%	-73341.0%	-14710.9%	-644.8%	-101.1%	▲ 544 pts
Return on assets (ROA)	-64.1%	-52.5%	-77.2%	-67.2%	-27.2%	▲ 40 pts
Return on equity (ROE)	-77.3%	-87.0%	-190.2%	-137.3%	-46.8%	▲ 90 pts
Free cash flow margin	-29610.1%	-64875.5%	-13485.6%	-578.5%	-136.2%	▲ 442 pts
Current ratio	4.02×	6.08×	5.60×	5.44×	4.88×	▼ 10%
Quick ratio	—	6.08×	5.58×	5.44×	4.87×	▼ 10%
Debt to equity	0.00×	0.41×	1.07×	0.69×	0.50×	▼ 27%
Interest coverage	-108.59×	-36.24×	—	—	—	—

LXRX price history

Price history is added with the daily price update and will appear after the next one.

Similar companies

Sector leaderboards

BB Biotech AGBBZA.DE100/ 100

Arbutus Biopharma CorporationABUS97/ 100

Q32 Bio Inc.QTTB97/ 100

Bringing the fundamentals into focus…

Overall health

Strength: growing faster than most peersgrowing faster than peers

Strength: lower risk than most peers: more short-term liquiditylower risk: more liquidity

Drawback: less profitable than most peersless profitable than peers

Drawback: its shares are priced higher than most peers relative to what it earnspriced higher than peers for its earnings

Drawback: its share price swings more than most peers’ (beta 1.08 vs a peer median of 0.63)bigger price swings (beta 1.08 vs peers 0.63)

Ranks #671 of 1,157 healthcare companies (bottom 43%)

See how it ranks against its peers

Worth knowing

Stock-based pay is a large cost. Stock pay was 25% of revenue in 2025.

Lexicon Pharmaceuticals paid employees $13M in stock in 2025, 25% of its $50M revenue. It doesn't use cash, so it flatters cash flow, but it is a real cost to shareholders through dilution.

Valuation signals disagree. Cheaper than 50% of peers on free cash flow, but only 0% on earnings.

Relative to its free cash flow, Lexicon Pharmaceuticals looks cheaper than 50% of peers; relative to its earnings, cheaper than only 0%. The valuation score blends the two, so look at which measure fits this business best.

Not profitable yet. Reported a loss in the 12 months to June 2026.

Lexicon Pharmaceuticals reported a net loss over the last twelve months, so earnings-based measures can't show it as cheap.

Revenue is falling. Revenue fell 29% in the 12 months to June 2026 vs the 12 months before.

Lexicon Pharmaceuticals's revenue fell 29% in the 12 months to June 2026 vs the 12 months before.

Questions investors ask about Lexicon Pharmaceuticals

Is Lexicon Pharmaceuticals getting weaker?

Its latest SEC filing (Aug 6, 2026) got weaker in some ways: 12-month revenue fell 40.5%. Its overall score is unchanged at 48/100 since Oct 28, 2026.

How is Lexicon Pharmaceuticals valued vs its peers?

Priced higher than most peers relative to what it earns. Valuation scores 8/100 against 1,393 healthcare peers. Earnings yield -9.4% vs a peer median of 1.5% (weaker than 100% of peers).Earnings yield -9.4% vs peers 1.5% (weaker than 100% of peers).

Is Lexicon Pharmaceuticals growing?

Yes, faster than most of its peers. Growth scores 81/100 against 1,393 healthcare peers. 3-year revenue growth 367.1% vs a peer median of 5.8% (stronger than 95% of peers).3-year revenue growth 367.1% vs peers 5.8% (stronger than 95% of peers). Revenue growth -29.0% vs a peer median of 6.1% (weaker than 93% of peers).Revenue growth -29.0% vs peers 6.1% (weaker than 93% of peers).

How profitable is Lexicon Pharmaceuticals?

Less profitable than most of its peers. Profitability scores 16/100 against 1,393 healthcare peers. Operating margin -131.4% vs a peer median of 7.1% (weaker than 88% of peers).Operating margin -131.4% vs peers 7.1% (weaker than 88% of peers).

How risky is Lexicon Pharmaceuticals?

Lower risk relative to 1,393 healthcare peers, judged on debt, liquidity and share-price swings. Current ratio 13.37× vs a peer median of 2.59× (stronger than 91% of peers).Current ratio 13.37× vs peers 2.59× (stronger than 91% of peers). Beta 1.08 vs a peer median of 0.63 (weaker than 75% of peers).Beta 1.08 vs peers 0.63 (weaker than 75% of peers). A relative measure, not a bankruptcy probability.

Previous quarter

Latest quarter

Change

Revenue (12 months)

69.6M USD

41.5M USD

−40.5%

Net income (12 months)

−26.1M USD

−61.1M USD

+134.3%

Operating margin

-34.8%

-131.4%

−96.6 pts

Debt

49.7M USD

51.4M USD

+3.5%

Cash

38.1M USD

40.9M USD

+7.4%

Shares outstanding

444.2M

445.0M

+0.2%

Key ratios

FY 2021

FY 2022

FY 2023

FY 2024

FY 2025

Change

Gross margin

100.0%

92.9%

98.0%

99.4%

▲ 1.4 pts

Operating margin

-29224.8%

-72489.2%

-14265.0%

-634.2%

-98.2%

▲ 536 pts

Net margin

-29449.0%

-73341.0%

-14710.9%

-644.8%

-101.1%

▲ 544 pts

Return on assets (ROA)

-64.1%

-52.5%

-77.2%

-67.2%

-27.2%

▲ 40 pts

Return on equity (ROE)

-77.3%

-87.0%

-190.2%

-137.3%

-46.8%

▲ 90 pts

Free cash flow margin

-29610.1%

-64875.5%

-13485.6%

-578.5%

-136.2%

▲ 442 pts

Current ratio

4.02×

6.08×

5.60×

5.44×

4.88×

▼ 10%

Quick ratio

—

6.08×

5.58×

5.44×

4.87×

▼ 10%

Debt to equity

0.00×

0.41×

1.07×

0.69×

0.50×

▼ 27%

Interest coverage

-108.59×

-36.24×

—